Adapt Pharma facilitates NARCAN® (naloxone hydrochloride) Nasal Spray access to state and local public entities
January 14, 2016
U.S. Communities Purchasing Alliance Members Gain Access to Opioid Overdose Treatment at Discounted Public Interest Price
Dublin, Ireland – January 14, 2016 – In support of White House efforts to address the opioid overdose epidemic and today’s community forum in Knoxville, Tennessee, Adapt Pharma, Limited (“Adapt Pharma”) today announced that it has reached an agreement to facilitate the purchase of NARCAN Nasal Spray by offering its discounted Public Interest Price to 62,000 agencies in state and local government and the non-profit sector.
Adapt Pharma, in partnership with the National Association of Counties, National Governors Association, National League of Cities and United States Conference of Mayors, will offer NARCAN Nasal Spray at a discounted Public Interest Price of $37.50 per dose ($75 for a 2 pack carton) through the U.S. Communities Purchasing Alliance andPremier, Inc. To learn more click here or call 844-4-NARCAN.
NARCAN Nasal Spray is the only FDA approved, ready-to-use, nasal spray version of naloxone hydrochloride, indicated for the emergency treatment of opioid overdose. It is not a substitute for emergency medical care. See below for indication and important safety information.
“This broad partnership provides state and local government and non-profit entities access to NARCAN Nasal Spray, the only FDA approved, needle-free, ready-to-use naloxone nasal spray, at a transparent discounted price,” said Seamus Mulligan, Chairman and CEO of Adapt Pharma. “With this partnership, we are confident NARCAN Nasal Spray can play a critical role in supporting these entities’ efforts to implement scaled-up naloxone access and distribution policies in response to the growing opioid overdose crisis in communities across the nation.”
“U.S. Communities, along with our partners, are proud to have joined forces with Adapt Pharma to help fight this epidemic and to facilitate public agencies’ access to this potentially lifesaving medication,” said Chris Robb, General Manager of U.S. Communities.
This partnership comes as deaths from opioid-based prescription painkillers and heroin have reached epidemic proportions in the U.S., surging to over 29,000 in 2014, according to figures released in December 2015 by the Centers for Disease Control and Prevention.
Adapt Pharma’s discounted Public Interest Price is available to Qualifying Group Purchasers, such as law enforcement, fire fighters, first responders, departments of health, local school districts, colleges and universities, and community-based organizations. Click here for further details or call 844-4-NARCAN.